Clinical trials: Cancer Disease Progression
Hormone-refractory Prostate Cancer
Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel
This is a Phase II, non-randomized, open label study of ILX651 in patients with hormone-refractory prostate cancer previously treated with docetaxel.
- Trial name
- NCT00082134
- Testing
- ILX651
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Colorectal Cancer
An Observational Study of Avastin in Participants With Metastatic Colorectal Cancer (KORALLE)
This observational multicenter study will evaluate the differences in progression-free survival defined in specific subgroups of participants with metastatic colorectal cancer receiving bevacizumab (Avastin).
- Trial name
- NCT01775644
- Testing
- Bevacizumab
- Volunteers
- 3,003 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Prospective Longitudinal Breast Cancer Study
The purpose of this study is to obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of breast cancer.
- Trial name
- NCT02270931
- Testing
- CA 15-3 Assay
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- Fujirebio Diagnostics, Inc.
Urothelial Carcinoma
Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy
This is a single-arm, single-site pilot of Radium-223 (55 kBq/kg) IV q3 weeks for up to 6 doses in combination with Atezolizumab 1200mg IV once every 3 weeks until investigator determined lack of benefit, unacceptable toxicity…
- Trial name
- NCT03208712
- Testing
- Atezolizumab, Radium-223
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan Rogel Cancer Center
Neuroendocrine Tumors
Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor
The purpose of this study is to compare streptozotocin (STZ) vs everolimus as first line treatment for advanced pNET and to elucidate which sequence of STZ based chemotherapy and the mammalian Target of Rapamycin (mTOR)…
- Trial name
- SEQTOR (NCT02246127)
- Testing
- Drug: Everolimus, STZ-5FU
- Where
- 37 sites in Denmark, France and 6 more
- Volunteers
- 141 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Central Nervous System Metastases, HER2-positive Breast Cancer
Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
This is a phase 1b/2 study to evaluate the safety and clinical activity of the combination of lapatinib, everolimus and capecitabine for the treatment of participants with HER2+ breast cancer with metastases in the brain who have…
- Conditions
- Central Nervous System Metastases, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01783756
- Testing
- lapatinib ditosylate, everolimus, capecitabine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jonsson Comprehensive Cancer Center
HER2-positive Breast Cancer
Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
This is an open-label, multicenter, phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics of the combination of tucatinib-Oral VP16-trastuzumab in patients with HER2-positive metastatic breast cancer…
- Trial name
- TUC-TOC (NCT05955170)
- Testing
- Tucatinib in Combination of Oral VP16 and trastuzumab
- Where
- 13 sites in France
- Volunteers
- 66 people
- Sponsor
- Institut Curie
Malignant Gliomas
Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months.
- Trial name
- NCT00463073
- Testing
- Cetuximab, Bevacizumab, Irinotecan
- Where
- 3 sites in Denmark
- Volunteers
- 32 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Diffuse Large B-cell Lymphoma
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00474188
- Testing
- CC-5013 (lenalidomide), dexamethasone
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- Celgene Corporation
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase III trial studies whether changes in diet and physical activity can increase the length of survival without the return of cancer (progression-free survival) compared with usual care in patients with…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT00719303
- Testing
- Behavioral Dietary Intervention, Compliance Monitoring, Counseling
- Where
- 687 sites in United States
- Volunteers
- 1,070 people
- Sponsor
- Gynecologic Oncology Group
Endocrine Tumors
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.
- Trial name
- CLARINET (NCT00353496)
- Testing
- lanreotide (Autogel formulation)
- Where
- 71 sites in United States, Austria and 13 more
- Volunteers
- 264 people
- Sponsor
- Ipsen
Oral Squamous Cell Carcinoma (OSCC)
Salivary IL-6 and Interleukin Gene Polymorphisms in Oral Squamous Cell Carcinoma
This observational study will evaluate whether salivary interleukin-6 levels and selected interleukin gene polymorphisms are associated with regional lymph node involvement in patients with oral squamous cell carcinoma.
- Trial name
- IL6-OSCC (NCT07692360)
- Testing
- Saliva Collection and Biomarker Analysis
- Where
- 2 sites in Italy
- Volunteers
- 38 people
- Sponsor
- University of Pavia
Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Role of BMP Pathway in MDS Progression
Myelodysplastic syndromes (MDS) are hematological cancers that can progress to acute myelogenous leukemia (AML). The involvement of the microenvironment in the maintenance, resistance and evolution of MDS is increasingly…
- Trial name
- BMP-MDS (NCT06175923)
- Testing
- Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Hospices Civils de Lyon
Cervical Cancer
A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy
This is a single-arm, open-label, multicentre, phase II clinical study.Subjects can only enter this study after they meet the inclusion and exclusion criteria.All enrolled patients will receive the treatment with HLX10 combined…
- Trial name
- NCT04150575
- Testing
- HLX10+Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Henlius Biotech
Colorectal Cancer
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as liposomal SN-38, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00311610
- Testing
- SN-38 liposome
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Ovarian Carcinoma
Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy
Preclinical studies showed that metronomic chemotherapy can induce tumor regression secondary to apoptosis of the tumor blood vessels. This effect was increased by combining metronomic chemotherapy with anti-angiogenic drugs.
- Trial name
- NCT01175772
- Testing
- Cytophosphan, Celecoxib, Methotrexate
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- HaEmek Medical Center, Israel
Non Small Cell Lung Cancer
Third-line Treatment of Gefitinib in NSCLC Patients
The purpose of this study is to evaluate the disease control rate (DCR) of gefitinib as third-line retreatment in stage IIIB/IV NSCLC with EGFR 19del/L858R positive mutation patients who had benefited from first-line gefitinib…
- Trial name
- NCT01933347
- Testing
- Gefitinib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Guangdong Association of Clinical Trials
Sarcoma
Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype
This is a randomized open label study, with 2 arms treatments conducted in patients with metastatic or unresectable advanced sarcoma of rare subtype; previously treated by anthracycline-based regimen except for whom standard…
- Trial name
- RAR-Immune (NCT04741438)
- Testing
- Nivolumab and IPILIMUMAB, Pazopanib Oral Tablet [Votrient]
- Where
- 13 sites in France
- Volunteers
- 96 people
- Sponsor
- Centre Leon Berard
Triple Negative Breast Cancer
Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib
[Background]: Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen and progesterone receptor as well as human epidermal growth factor receptor 2 (HER-2).
- Trial name
- NCT02511847
- Testing
- Afatinib
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Glioblastoma Multiforme
Determination of Immune Phenotype in Glioblastoma Patients
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Despite intensive research efforts and a multimodal management that actually consists of surgery, radiotherapy and chemotherapy with temozolomide…
- Trial name
- NCT02751138
- Testing
- Surgery
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University of Ulm
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.